Adma Biologics (ADMA) Receivables (2012 - 2026)
Adma Biologics' (ADMA) quarterly Receivables came in at $158.4 million in Q4 2025, up 216.86% YoY from $50.0 million in Q4 2024, and up 15.08% on a QoQ basis from $137.7 million in Q3 2025.
Adma Biologics (ADMA) Receivables (2012 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Receivables data on file, last reported at $158.4 million in Q4 2025.
- Quarterly Receivables rose 216.86% year-over-year to $158.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158.4 million (up 216.86% YoY) and the FY2025 annual result came in at $158.4 million, up 216.86% from the prior year.
- Receivables rose to $158.4 million in Q4 2025, from $137.7 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $158.4 million in Q4 2025 to a low of $15.4 million in Q1 2021.
- A 5-year average of $48.8 million and a median of $29.3 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables sank 45.74% — and 2025, when it jumped 264.54%.
- Tracing ADMA's Receivables over 5 years: stood at $28.6 million in 2021, then slumped by 45.74% to $15.5 million in 2022, then surged by 76.85% to $27.4 million in 2023, then soared by 82.34% to $50.0 million in 2024, then soared by 216.86% to $158.4 million in 2025.
- The last three Receivables figures came in at $158.4 million (Q4 2025), $137.7 million (Q3 2025), and $109.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 138.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.23 Mn |
| Dec 31, 2025 | 158.43 Mn |
| Sep 30, 2025 | 137.67 Mn |
| Jun 30, 2025 | 109.73 Mn |
| Mar 31, 2025 | 99.41 Mn |
| Dec 31, 2024 | 50.00 Mn |
| Sep 30, 2024 | 50.14 Mn |
| Jun 30, 2024 | 30.10 Mn |
| Mar 31, 2024 | 49.62 Mn |
| Dec 31, 2023 | 27.42 Mn |
| Sep 30, 2023 | 31.32 Mn |
| Jun 30, 2023 | 36.73 Mn |
| Mar 31, 2023 | 26.52 Mn |
| Dec 31, 2022 | 15.51 Mn |
| Sep 30, 2022 | 20.90 Mn |
| Jun 30, 2022 | 18.88 Mn |
| Mar 31, 2022 | 25.63 Mn |
| Dec 31, 2021 | 28.58 Mn |
| Sep 30, 2021 | 20.39 Mn |
| Jun 30, 2021 | 23.54 Mn |